Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

A Medscape Oncology exclusive preview

Medscape delivers dynamic, innovative education to optimize learner engagement and patient outcomes worldwide. We are the largest medical education provider, delivering precision education for actionable outcomes across 30+ specialties in...

Medscape Education

What does the future hold for clinical trial recruitment?

The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...

Page & Page Health

- PMLiVE

New Pfizer initiative, ‘An Accord for a Healthier World’, launched to improve global health equity

The company aims to provide support for 1.2 billion people in 45 lower-income countries

- PMLiVE

Results released from new study of AstraZeneca’s COVID-19 antibody

A new study from Oxford University shows that Evusheld is effective in protecting against emerging Omicron variants

- PMLiVE

Takeda and Daiichi Sankyo collaborate to create wearable device

Takeda and Daiichi Sankyo have announced that they will work on a new research project, along with Tohoku University and MICIN, a digital health and telemedicine company, to develop a...

Part 1 of the Medscape video interview series

Ahead of  Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr Loretta Nastoupil on the most important abstracts to look out for at EHA in lymphoma...

Medscape Education

- PMLiVE

NHS England appoints Chris Hopson as its new chief strategy officer

Hopson previously served as chief executive of NHS Providers

- PMLiVE

Almirall launches Actinic Keratosis Global Day during Skin Cancer Awareness Month

The global event will take place annually on 24 May to increase awareness of skin cancer

- PMLiVE

Pfizer/BioNTech COVID-19 vaccine produces strong immune response in children

A third dose of the vaccine has been trialled in children aged from six months to under five years old

- PMLiVE

AbbVie submits Parkinson’s disease therapy to FDA

The therapy offers a first-of-its-kind, 24-hour, continuous subcutaneous delivery

- PMLiVE

Sanofi and Regeneron receive FDA approval for eosinophilic oesophagitis treatment

Dupixent is the first and only drug specifically recommended for EoE in the US

- PMLiVE

AstraZeneca’s COVID-19 vaccine receives EMA approval for use as third-dose booster

Vaxzevria is a ‘viral vector’ vaccine, a technology that is also used to create vaccines for other infectious diseases like flu, HIV and Ebola

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links